When Digital Transformation in Pharma Breaks, Look at the Business Analyst
Image reference: / source
Digital transformation in Pharma R&D rarely fails because the technology is inadequate. Platforms are powerful, cloud infrastructure is mature, and tooling continues to evolve faster than most organizations can absorb.
And yet, many initiatives still stall, underdeliver, or quietly lose momentum once systems go live.
The root cause is often less visible — and far more structural.
It sits at the intersection between science, technology, and business decision-making. Specifically, in how organizations define and enable the Business Analyst role in scientific environments.
The Limits of the Traditional BA Model
Historically, Business Analysts have been positioned as translators. They gather requirements from business stakeholders, convert them into functional specifications, and work with IT teams to drive implementation.
This model works reasonably well in transactional or process-driven domains and industries. It breaks down, however, when applied unchanged to science-focussed industries such as Biotech, Pharma, Chemicals, Food & Beverage and so on.
In lab environments, requirements are rarely static, fully articulated, or even consciously understood by the people performing the work. Critical steps live in muscle memory. Metadata dependencies are inherited from legacy practices. Workarounds evolve to protect experimental integrity, not to satisfy process diagrams.
When a BA approaches this landscape without scientific context, several things tend to happen:
- Scientists feel misunderstood or oversimplified
- Requirements surface late, if at all
- Systems reflect “how work should happen,” not how it actually does
- Adoption becomes an exercise in change management rather than trust
The result isn’t failure in a dramatic sense. It’s something quieter and more costly: partial usage, parallel workflows, and gradual erosion of confidence in digital systems.
A Common Pattern in Advanced Research Domains
This tension becomes especially visible in data-intensive areas such as proteomics and multi-omics research.
The priorities entering a digital initiative are often divergent:
- Scientists focus on data accuracy, reproducibility, and experimental nuance
- IT teams prioritize scalability, stability, and architectural coherence
- Business stakeholders seek visibility, standardization, and insight across studies
None of these objectives are inherently incompatible. The problem arises when they are interpreted independently, without a unifying layer of scientific understanding during requirement discovery and design.
In these situations, the BA is expected to mediate alignment — yet without fluency in the science itself, that mediation is limited to surface-level translation. Important assumptions remain implicit. Risk is identified late. Decisions are made without fully understanding their impact on downstream science.
From Translation to Interpretation
What these environments require is not simply better documentation or more stakeholder meetings. They require a different posture from the BA role altogether.
The most effective BAs operating in scientific informatics settings act less as translators and more as interpreters. They understand enough of the underlying science to ask meaningful “why” questions. They recognize when a seemingly minor workflow step carries regulatory or experimental significance. They know when a request for flexibility is a request for scientific protection.
This science-first approach changes the nature of discovery:
- Requirements are grounded in real experimental workflows, not idealized process maps
- Edge cases surface early, before they become rework
- IT teams receive context, not just specifications
- Business leaders gain visibility into trade-offs without compromising scientific rigor
Lately, science-first approach is beginning to gain prominence in the life sciences industry as well. Nearly 8 in 10 pharma leaders anticipate that scientific expertise will carry greater weight in sourcing evaluations over the next three years, with 4 in 10 already viewing it as a key future differentiator, as per Everest Group in a report titled “Embedding Scientific Expertise at the Core of Life Sciences IT Delivery”. https://zifornd.com/news/zifo-highlights-new-everest-group-report-showcasing-critical-need-for-science-first-it-delivery/
Hence, scientific context becomes extremely critical in business analysis.
When scientific context is embedded early in business analysis, the effects are visible across multiple dimensions of delivery. Across complex R&D digital initiatives, a consistent set of outcome patterns tends to emerge.
Observed Impact of Science‑First Business Analysis in R&D Digital Programs
| Impact Area | What Changes When Scientific Context Is Embedded |
|---|---|
| Requirements Accuracy | Fewer late‑stage surprises as tacit lab workflows are surfaced early and translated into implementable requirements |
| Implementation Time | Reduced rework due to early identification of scientific edge cases and constraints |
| User Adoption | Faster, organic uptake driven by workflows that feel familiar rather than imposed |
| Scientific Confidence | Greater trust in data pipelines as validation logic aligns with experimental rigor |
| Stakeholder Alignment | Earlier convergence between science, IT, and business through shared understanding rather than negotiation |
Seeing the Full Workflow
One of the most consistent blind spots in digital R&D initiatives is the assumption that workflows begin and end within systems.
In reality, data journeys in the lab are fragmented. They pass through instruments, spreadsheets, notebooks, interim scripts, emails, and human handoffs. Informal documentation fills gaps left by formal tools.
When BAs rely primarily on interviews or pre-existing SOPs, much of this reality remains invisible. It is only through close observation — watching how experiments are actually run, how exceptions are handled, and how trust is built around data — that unspoken requirements emerge.
These requirements are rarely dramatic. They are often small: a metadata field that must remain editable, a review step that cannot be automated, a naming convention that encodes historical meaning. But collectively, they determine whether a system feels usable or intrusive.
Rethinking Vendor and Platform Evaluation
The same science-aligned lens applies when evaluating platforms.
Vendor demonstrations frequently showcase breadth of features. What they rarely expose is how a system behaves under the strain of real experimental complexity.
More effective evaluations stress-test platforms using authentic scenarios:
- Non-ideal data sets
- Incomplete or evolving metadata
- Workflow deviations that reflect real lab behavior
- Regulatory expectations that extend beyond checkbox compliance
When evaluation criteria are grounded in scientific reality rather than abstract capabilities, decision-making shifts. Platforms are chosen not for how impressive they appear, but for how resilient they are in practice.
Adoption Without Resistance
One of the clearest indicators of alignment is what happens after go-live.
Systems designed with scientific empathy tend to see a different adoption pattern. Training feels familiar rather than imposed. Users recognize their own workflows in the interface. Resistance gives way to cautious trust — and eventually to advocacy.
This does not happen because scientists suddenly enjoy new tools. It happens because the systems respect the logic of their work.
Two Models of the BA Role in Scientific Informatics
Across pharma and biotech, two broad models of business analysis continue to coexist:
Process-first BA models emphasize consistency, standardization, and functional completeness. They often struggle with scientific nuance and generate downstream rework.
Science-First BA models prioritize understanding the experimental reality before formalizing requirements. They surface risk early, reduce iteration, and create systems that feel credible to scientific users.
The difference between the two is not talent. It is orientation.
Two Approaches to Business Analysis in Scientific Informatics
| Without Science-First BA | With Science-First BA |
|---|---|
| Scientists feel ignored | Scientists become active partners because the BA speaks their language |
| Requirements need rework | Requirements land right the first time |
| Tools don’t fit reality | Workflows mirror true lab practice – the BA ensures workflows reflect real-world practices, not just theoretical designs. |
| Resistance to adoption | System advocacy from within — adoption accelerates as the BA champions usability, minimizes friction, and frames benefits in terms scientists care about. |
| Oversold vendor features | Decisions are grounded in evidence because the BA designs evaluations using authentic sample sets and tests vendor claims under real conditions. |
A Role Evolution, Not a Niche Skillset
As R&D organizations continue to digitize, the need for science-first BAs will only increase. This is not a call for every BA to become a scientist. It is a recognition that in scientific environments, digital success depends on contextual fluency.
Effective BAs in these settings consistently demonstrate:
- Strong scientific literacy
- Comfort navigating ambiguous workflows
- Awareness of regulatory implications
- Strong listening and observational skills
Most importantly, they understand that science is not just another business process. It is a knowledge-generating activity, and digital systems must be designed to protect that purpose.
Closing Reflection
Digital transformation in pharma is often discussed in terms of platforms, data strategies, and operating models. Less attention is paid to the roles that translate ambition into execution.
The Business Analyst — when grounded in scientific context — becomes one of the most consequential of those roles.
Because when systems honor how science actually works, change does not need to be forced. It is accepted, adopted, and sustained.
And that is where transformation becomes real.
